{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T23:34:10Z","timestamp":1740180850330,"version":"3.37.3"},"reference-count":26,"publisher":"Consilium Medicum","issue":"9","license":[{"start":{"date-parts":[[2019,9,15]],"date-time":"2019-09-15T00:00:00Z","timestamp":1568505600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Terapevticheskii arkhiv"],"abstract":"<jats:p>Hypertension is one of the most important risk factors for cardiovascular diseases (CVD) in the world, including Russia. Current Guidelines for the management of arterial hypertension do not include different theatment strategies for men and women. Gender and age analysis of antihypertensive treatmen in men and women could reveal unreasonable and non - optimal treatment in each group. The purpose of this study was to identify the gender features of antihypertensive therapy used by primary care physicians in patients with hypertension. Materials and methods. The study is based on the Arterial Hypertension Registry established in 2012. The methodology of it has been described previously [1]. Medical data from outpatient cards were entered by doctors of 53 city primary care medical centers and 5 cardiology clinics from 22 regions of the Russian Federation. The study included the data of 33 564 patients from 18 years and older with diagnosis of arterial hypertension. Gender, age, height, body weight, smoking status, office blood pressure (BP), laboratory and instrumental examination methods, diagnosed cardiovascular and cerebrovascular diseases and comorbidities in accordance with the International Classification of Diseases of the 10th revision [ICD-10], as well as the treatment (antihypertensive and lipid - lowering therapy) were listed. Results and conclusion. Gender differences in the prescription antihypertensive therapy (AHT) in men and women with hypertension were revealed. Apparently, one of the reasons for these differences is the earlier and more frequent development of cardiovascular and cerebrovascular complications of hypertension in men than in women. Beta - blockers (BB) and angiotensin - converting enzyme inhibitors (ACEi) are more often prescribed to men with hypertension and with coronary artery disease (CAD), myocardial infarction (MI) and chronic heart failure (CHF). Women with hypertension are more often prescribed angiotensin receptor blockers (ARB), thiazide and thiazide - like diuretics. The study also showed non - optimal treatment of patients with hypertension. Insufficient prescription of medication which could improve the prognosis of the disease (ACE inhibitors \/ARB, BB, mineralocorticoid receptor antagonist) have been identified in patients with hypertension and CAD, MI, CHF. It is noteworthy that in the some outpatient cards of patients with AH there is no record of AHT prescription: at a young age - in 9.6%, at old age in 15.1% of cards. Despite the fact of high and very high cardiovascular risk of the majority of patients, lipid - lowering therapy (statins) was prescribed insufficiently. The most statin administration was observed in hypertensive patients with coronary artery disease (50.1%) and myocardial infarction (62.7%).<\/jats:p>","DOI":"10.26442\/00403660.2019.09.000356","type":"journal-article","created":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T13:53:16Z","timestamp":1571838796000},"page":"88-100","source":"Crossref","is-referenced-by-count":1,"title":["Antihypertensive therapy in men and women in real clinical practice according to the National register"],"prefix":"10.26442","volume":"91","author":[{"given":"E V","family":"Oshhepkova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A V","family":"Aksenova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A A","family":"Orlovskij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I E","family":"Chazova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18344","published-online":{"date-parts":[[2019,9,15]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"\u041e\u0449\u0435\u043f\u043a\u043e\u0432\u0430 \u0415.\u0412., \u041b\u0430\u0437\u0430\u0440\u0435\u0432\u0430 \u041d.\u0412., \u0427\u0430\u0437\u043e\u0432\u0430 \u0418.\u0415. \u041e\u0446\u0435\u043d\u043a\u0430 \u043a\u0430\u0447\u0435\u0441\u0442\u0432\u0430 \u043e\u0431\u0441\u043b\u0435\u0434\u043e\u0432\u0430\u043d\u0438\u044f \u0431\u043e\u043b\u044c\u043d\u044b\u0445 \u0430\u0440\u0442\u0435\u0440\u0438\u0430\u043b\u044c\u043d\u043e\u0439 \u0433\u0438\u043f\u0435\u0440\u0442\u043e\u043d\u0438\u0435\u0439 \u0432 \u043f\u0435\u0440\u0432\u0438\u0447\u043d\u043e\u043c \u0437\u0432\u0435\u043d\u0435 \u0437\u0434\u0440\u0430\u0432\u043e\u043e\u0445\u0440\u0430\u043d\u0435\u043d\u0438\u044f (\u043f\u043e \u0434\u0430\u043d\u043d\u044b\u043c \u0440\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u043e\u0433\u043e \u0420\u0435\u0433\u0438\u0441\u0442\u0440\u0430 \u0430\u0440\u0442\u0435\u0440\u0438\u0430\u043b\u044c\u043d\u043e\u0439 \u0433\u0438\u043f\u0435\u0440\u0442\u043e\u043d\u0438\u0438). \u0421\u0438\u0441\u0442\u0435\u043c\u043d\u044b\u0435 \u0433\u0438\u043f\u0435\u0440\u0442\u0435\u043d\u0437\u0438\u0438. 2017;2:29-34.","DOI":"10.26442\/2075-082X_14.2.29-34"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Lim S.S, Vos T, Flaxman A.D, Danaei G, Shibuya K, Adair-Rohani H, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224-60.","DOI":"10.1016\/S0140-6736(12)61766-8"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60655-8"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.26442\/2075082X.2019.1.190179"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Turnbull F, Woodward M, Neal B, et al. Do men and women respond differently to blood pressure - lowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart J. 2008;29:2669-80.","DOI":"10.1093\/eurheartj\/ehn427"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Gu Q, Burt V.L, Paulose-Ram R, Dillon C.F. Gender differences in hypertension treatment, drug utilization patterns, and blood pressure control among US adults with hypertension: data from the National Health and Nutrition Examination Survey 1999-2004. Am J Hypertens. 2008;21:789-98.","DOI":"10.1038\/ajh.2008.185"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Qvarnstr\u20acom M, Wettermark B, Ljungman C, Zarrinkoub R, Hasselstr Eom J, Manhem K, et al. Antihypertensive treatment and control in a large primary care population of 21,167 patients. J Hum Hypertens. 2011;25:484-91.","DOI":"10.1038\/jhh.2010.86"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Klungel O.H, de Boer A, Paes A.H, Seidell J.C, Bakker A. Sex differences in antihypertensive drug use: determinants of the choice of medication for hypertension. J Hypertens. 1998;16:1545-53.","DOI":"10.1097\/00004872-199816100-00021"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Keyhani S, Scobie J.V, Hebert P.L, Mc Laughlin M.A.Gender disparities in blood pressure control and cardiovascular care in a national sample of ambulatory care visits. Hypertension. 2008;51:1149-55.","DOI":"10.1161\/HYPERTENSIONAHA.107.107342"},{"key":"ref10","unstructured":"Fletcher A, Beevers D.G, Bulpitt C, et al. Beta adrenoceptor blockade is associated with increased survival in male but not female hypertensive patients: a report from the DHSS Hypertension Care Computing Project (DHCCP). J Hum Hypertens. 1988;2:219-27."},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Jansen J, Bonner C, Mc Kinn S, et al. General practitioners' use of absolute risk versus individual risk factors in cardiovascular disease prevention: an experimental study. BMJ OPEN. 2014;4:e004812.","DOI":"10.1136\/bmjopen-2014-004812"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Kloner R.A, Sowers J.R, Di Bona G.F, et al. Sex - and age - related antihypertensive effects of amlodipine. The Amlodipine Cardiovascular Community Trial Study Group. Am J Cardiol.1996;77:713-22.","DOI":"10.1016\/S0002-9149(97)89205-3"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Igho Pemu P, Ofili E. Hypertension in women: part I. J Clin Hypertens (Greenwich). 2008;10:406-10.","DOI":"10.1111\/j.1751-7176.2008.06552.x"},{"key":"ref14","unstructured":"\u0427\u0430\u0437\u043e\u0432\u0430 \u0418.\u0415., \u0410\u043a\u0441\u0435\u043d\u043e\u0432\u0430 \u0410.\u0412., \u041e\u0449\u0435\u043f\u043a\u043e\u0432\u0430 \u0415.\u0412. \u041e\u0441\u043e\u0431\u0435\u043d\u043d\u043e\u0441\u0442\u0438 \u0442\u0435\u0447\u0435\u043d\u0438\u044f \u0430\u0440\u0442\u0435\u0440\u0438\u0430\u043b\u044c\u043d\u043e\u0439 \u0433\u0438\u043f\u0435\u0440\u0442\u043e\u043d\u0438\u0438 \u0443 \u043c\u0443\u0436\u0447\u0438\u043d \u0438 \u0436\u0435\u043d\u0449\u0438\u043d (\u043f\u043e \u0434\u0430\u043d\u043d\u044b\u043c \u041d\u0430\u0446\u0438\u043e\u043d\u0430\u043b\u044c\u043d\u043e\u0433\u043e \u0440\u0435\u0433\u0438\u0441\u0442\u0440\u0430 \u0430\u0440\u0442\u0435\u0440\u0438\u0430\u043b\u044c\u043d\u043e\u0439 \u0433\u0438\u043f\u0435\u0440\u0442\u043e\u043d\u0438\u0438). \u0422\u0435\u0440\u0430\u043f\u0435\u0432\u0442\u0438\u0447\u0435\u0441\u043a\u0438\u0439 \u0430\u0440\u0445\u0438\u0432. 2019;91(01):4-12."},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Thomopoulos C, Parati G, Zanchetti A. Effects of blood - pressure - lowering treatment on outcome incidence. 12. Effects in individuals with high - normal and normal blood pressure: overview and meta - analyses of randomized trials. J Hypertens. 2017;35:2150-60.","DOI":"10.1097\/HJH.0000000000001547"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"\u0420\u0435\u043a\u043e\u043c\u0435\u043d\u0434\u0430\u0446\u0438\u0438 \u0415\u041e\u041a \u043f\u043e \u0432\u0435\u0434\u0435\u043d\u0438\u044e \u043f\u0430\u0446\u0438\u0435\u043d\u0442\u043e\u0432 \u0441 \u043e\u0441\u0442\u0440\u044b\u043c \u0438\u043d\u0444\u0430\u0440\u043a\u0442\u043e\u043c \u043c\u0438\u043e\u043a\u0430\u0440\u0434\u0430 \u0441 \u043f\u043e\u0434\u044a\u0435\u043c\u043e\u043c \u0441\u0435\u0433\u043c\u0435\u043d\u0442\u0430 ST 2017. \u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u0438\u0439 \u043a\u0430\u0440\u0434\u0438\u043e\u043b\u043e\u0433\u0438\u0447\u0435\u0441\u043a\u0438\u0439 \u0436\u0443\u0440\u043d\u0430\u043b. 2018;(5):103-58. https:\/\/doi.org\/10.15829\/1560-4071-2018-5-103-158","DOI":"10.15829\/1560-4071-2018-5-103-158"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Ponikowski P, Voors A, Anker D.S, Bueno H, Cleland G.F.J, Coats J.S.A, Falk V, Gonz\u00e1lez-Juanatey J, Harjola V, Jankowska A.E, Jessup M, Linde C, Nihoyannopoulos P, Parissis T.J, Pieske B, Riley P.J, Rosano M.C.G, Ruilope M.L, Ruschitzka F, Rutten H.F, van der Meer P. \u0420\u0435\u043a\u043e\u043c\u0435\u043d\u0434\u0430\u0446\u0438\u0438 ESH \u043f\u043e \u0434\u0438\u0430\u0433\u043d\u043e\u0441\u0442\u0438\u043a\u0435 \u0438 \u043b\u0435\u0447\u0435\u043d\u0438\u044e \u043e\u0441\u0442\u0440\u043e\u0439 \u0438 \u0445\u0440\u043e\u043d\u0438\u0447\u0435\u0441\u043a\u043e\u0439 \u0441\u0435\u0440\u0434\u0435\u0447\u043d\u043e\u0439 \u043d\u0435\u0434\u043e\u0441\u0442\u0430\u0442\u043e\u0447\u043d\u043e\u0441\u0442\u0438 2016. \u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u0438\u0439 \u043a\u0430\u0440\u0434\u0438\u043e\u043b\u043e\u0433\u0438\u0447\u0435\u0441\u043a\u0438\u0439 \u0436\u0443\u0440\u043d\u0430\u043b. 2017;(1):7-81. https:\/\/doi.org\/10.15829\/1560-4071-2017-1-7-81","DOI":"10.15829\/1560-4071-2017-1-7-81"},{"key":"ref18","unstructured":"National Institutes of Health N.H, Lung, and Blood Institute. Morbidity & Mortality: 2012 Chart Book on Cardiovascular, Lung, and Blood Diseases. Bethesda, MD: National Heart, Lung, and Blood Institute, 2012."},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"\u0411\u043e\u0439\u0446\u043e\u0432 \u0421.\u0410., \u0421\u0430\u043c\u043e\u0440\u043e\u0434\u0441\u043a\u0430\u044f \u0418.\u0412., \u041d\u0438\u043a\u0443\u043b\u0438\u043d\u0430 \u041d.\u041d., \u042f\u043a\u0443\u0448\u0438\u043d \u0421.\u0421., \u0410\u043d\u0434\u0440\u0435\u0435\u0432 \u0415.\u041c., \u0417\u0430\u0440\u0430\u0442\u044c\u044f\u043d\u0446 \u041e.\u0412., \u0411\u0430\u0440\u0431\u0430\u0440\u0430\u0448 \u041e.\u041b. \u0421\u0440\u0430\u0432\u043d\u0438\u0442\u0435\u043b\u044c\u043d\u044b\u0439 \u0430\u043d\u0430\u043b\u0438\u0437 \u0441\u043c\u0435\u0440\u0442\u043d\u043e\u0441\u0442\u0438 \u043d\u0430\u0441\u0435\u043b\u0435\u043d\u0438\u044f \u043e\u0442 \u043e\u0441\u0442\u0440\u044b\u0445 \u0444\u043e\u0440\u043c \u0438\u0448\u0435\u043c\u0438\u0447\u0435\u0441\u043a\u043e\u0439 \u0431\u043e\u043b\u0435\u0437\u043d\u0438 \u0441\u0435\u0440\u0434\u0446\u0430 \u0437\u0430 \u043f\u044f\u0442\u043d\u0430\u0434\u0446\u0430\u0442\u0438\u043b\u0435\u0442\u043d\u0438\u0439 \u043f\u0435\u0440\u0438\u043e\u0434 \u0432 \u0420\u0424 \u0438 \u0421\u0428\u0410 \u0438 \u0444\u0430\u043a\u0442\u043e\u0440\u043e\u0432, \u0432\u043b\u0438\u044f\u044e\u0449\u0438\u0445 \u043d\u0430 \u0435\u0435 \u0444\u043e\u0440\u043c\u0438\u0440\u043e\u0432\u0430\u043d\u0438\u0435. \u0422\u0435\u0440\u0430\u043f\u0435\u0432\u0442\u0438\u0447\u0435\u0441\u043a\u0438\u0439 \u0430\u0440\u0445\u0438\u0432. 2017;89(9):53-9. https:\/\/doi.org\/10.17116\/terarkh201789953-59","DOI":"10.17116\/terarkh201789953-59"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Ghosh M, Majumdar S.R. Antihypertensive medications, bone mineral density, and fractures: a review of old cardiac drugs that provides new insights into osteoporosis. Endocrine. 2014;46:397-405.","DOI":"10.1007\/s12020-014-0167-4"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Swedberg K, Zannad F, Mc Murray J.J, Krum H, van Veldhuisen D.J, Shi H, Vincent J, Pitt B. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol. 2012;59:1598-603.","DOI":"10.1016\/j.jacc.2011.11.063"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"\u0427\u0430\u0437\u043e\u0432\u0430 \u0418.\u0415., \u0416\u0435\u0440\u043d\u0430\u043a\u043e\u0432\u0430 \u042e.\u0412., \u041e\u0449\u0435\u043f\u043a\u043e\u0432\u0430 \u0415.\u0412., \u0428\u0430\u043b\u044c\u043d\u043e\u0432\u0430 \u0421.\u0410., \u042f\u0440\u043e\u0432\u0430\u044f \u0415.\u0411., \u041a\u043e\u043d\u0440\u0430\u0434\u0438 \u0410.\u041e., \u0411\u043e\u0439\u0446\u043e\u0432 \u0421.\u0410., \u041a\u0430\u0432\u0435\u0448\u043d\u0438\u043a\u043e\u0432 \u0412.\u0421., \u0421\u0435\u0440\u0435\u0431\u0440\u044f\u043a\u043e\u0432\u0430 \u0412.\u041d., \u0422\u0440\u0443\u0431\u0430\u0447\u0435\u0432\u0430 \u0418.\u0410. \u0420\u0430\u0441\u043f\u0440\u043e\u0441\u0442\u0440\u0430\u043d\u0435\u043d\u043d\u043e\u0441\u0442\u044c \u0444\u0430\u043a\u0442\u043e\u0440\u043e\u0432 \u0440\u0438\u0441\u043a\u0430 \u0441\u0435\u0440\u0434\u0435\u0447\u043d\u043e - \u0441\u043e\u0441\u0443\u0434\u0438\u0441\u0442\u044b\u0445 \u0437\u0430\u0431\u043e\u043b\u0435\u0432\u0430\u043d\u0438\u0439 \u0432 \u0440\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u043e\u0439 \u043f\u043e\u043f\u0443\u043b\u044f\u0446\u0438\u0438 \u0431\u043e\u043b\u044c\u043d\u044b\u0445 \u0441 \u0430\u0440\u0442\u0435\u0440\u0438\u0430\u043b\u044c\u043d\u043e\u0439 \u0433\u0438\u043f\u0435\u0440\u0442\u043e\u043d\u0438\u0435\u0439. \u041a\u0430\u0440\u0434\u0438\u043e\u043b\u043e\u0433\u0438\u044f. 2014;54(10):4-12.","DOI":"10.18565\/cardio.2014.10.4-12"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Gender differences in antihypertensive drug treatment: results from the Swedish Primary Care Cardiovascular Database (SPCCD) Charlotta Ljungman, Thomas Kahan, Linus Schi\u20acoler, Per Hjerpe, Jan Hasselstr\u20acom, Bjeorn Wettermark, Kristina Bengtsson Bostreom, Karin Manhem. J Am Society of Hypertension. 2014;8(12):882-90. http:\/\/dx.doi.org\/10.1016\/j.jash.2014.08.015","DOI":"10.1016\/j.jash.2014.08.015"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2008.09.038"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2009.09.014"}],"container-title":["Terapevticheskii arkhiv"],"original-title":[],"link":[{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/33641\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/33641\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T21:24:55Z","timestamp":1634160295000},"score":1,"resource":{"primary":{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/view\/33641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,15]]},"references-count":26,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,9,15]]}},"URL":"https:\/\/doi.org\/10.26442\/00403660.2019.09.000356","relation":{},"ISSN":["2309-5342","0040-3660"],"issn-type":[{"type":"electronic","value":"2309-5342"},{"type":"print","value":"0040-3660"}],"subject":[],"published":{"date-parts":[[2019,9,15]]}}}